MCID: PTN001
MIFTS: 53

Patent Foramen Ovale

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Patent Foramen Ovale

MalaCards integrated aliases for Patent Foramen Ovale:

Name: Patent Foramen Ovale 12 29 6 15
Foramen Ovale, Patent 44 73
Foramen Ovale Patent 12 55
Defect, Patent or Persistent, Ostium Secundum 12
Ostium Secundum Type Atrial Septal Defect 12
Atrial Septal Defect Within Oval Fossa 12
Ostium Secundum Atrial Septal Defect 53
Persistent Ostium Secundum 12
Asd Ostium Secundum Type 53
Ostium Secundum Asd 53
Osasd 53

Classifications:



External Ids:

Disease Ontology 12 DOID:13620
ICD10 33 Q21.1
MeSH 44 D054092
NCIt 50 C34619
UMLS 73 C0016522

Summaries for Patent Foramen Ovale

NIH Rare Diseases : 53 An ostium secundum atrial septal defect is a type of congenital heart defect called an atrial septal defect (ASD). An ASD is a hole in the wall (septum) between the two upper chambers of the heart (the atria). ASDs can be classified by location. An ostium secundum ASD is a hole in the center of the atrial septum. Normally, the right side of the heart pumps oxygen-poor blood to the lungs, while the left side pumps oxygen-rich blood to the body. An ASD allows blood from both sides to mix, causing the heart to work less efficiently. A small hole may not cause any symptoms or problems. A larger hole can eventually cause symptoms such as shortness of breath, respiratory infections, fainting, irregular heart rhythms or fatigue after mild activity. Larger ASDs can also ultimately lead to pulmonary artery hypertension, right ventricular hypertrophy (enlargement); SVT, or heart failure. Most cases of ASD are not inherited and occur by chance. Some cases appear to have autosomal dominant inheritance. Treatment may not be needed for small ASDs, which often close on their own. Larger ASDs are typically closed during childhood with open heart surgery or by cardiac catheterization.

MalaCards based summary : Patent Foramen Ovale, also known as foramen ovale, patent, is related to transposition of the great arteries and amaurosis fugax. An important gene associated with Patent Foramen Ovale is NKX2-5 (NK2 Homeobox 5), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Cardiac conduction. The drugs Clopidogrel and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Patent Foramen Ovale

Diseases related to Patent Foramen Ovale via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Related Disease Score Top Affiliating Genes
1 transposition of the great arteries 31.2 MED13L NKX2-5
2 amaurosis fugax 30.9 F5 MTHFR
3 pulmonary embolism 30.6 F2 F5 MTHFR SERPINC1
4 sticky platelet syndrome 30.6 F5 SERPINC1
5 thrombosis 30.3 F2 F5 MTHFR SERPINC1
6 branch retinal artery occlusion 30.3 F2 MTHFR SERPINC1
7 retinal artery occlusion 30.2 F2 F5 MTHFR SERPINC1
8 thrombophilia 30.1 F2 F5 MTHFR SERPINC1
9 stroke, ischemic 29.9 F2 F5 MTHFR SERPINC1
10 spinal cord infarction 29.8 F2 F5 MTHFR SERPINC1
11 thrombophilia due to thrombin defect 29.8 F2 F5 MTHFR SERPINC1
12 antiphospholipid syndrome 29.8 F2 F5 MTHFR SERPINC1
13 cerebrovascular disease 29.7 F12 F2 F5 MTHFR
14 pulmonary valve stenosis 29.7 GATA4 TBX5
15 atrial septal defect 4 29.6 GATA4 MYH6 NKX2-5 TBX20 TBX5
16 budd-chiari syndrome 29.6 F2 F5 MTHFR SERPINC1
17 hypoplastic left heart syndrome 29.5 MYH6 NKX2-5 TBX20
18 myocardial infarction 29.4 F2 F5 GATA4 MTHFR SERPINC1
19 atrial heart septal defect 27.8 F2 GATA4 MYH6 NKX2-5 TBX20 TBX5
20 heart disease 25.2 F2 GATA4 MTHFR MYH6 NKX2-5 SERPINC1
21 mental retardation and distinctive facial features with or without cardiac defects 11.4
22 right pulmonary artery, anomalous origin of, familial 11.4
23 tricuspid atresia 11.2
24 short stature, developmental delay, and congenital heart defects 11.2
25 right ventricle hypoplasia 11.2
26 aneurysm 10.8
27 atrial septal aneurysm 10.8
28 paracetamol poisoning 10.8 F2 F5
29 cerebral sinovenous thrombosis 10.7 F2 F5
30 hemoglobin e disease 10.7 F2 F5
31 inferior vena cava interruption 10.7 F5 MTHFR
32 cerebritis 10.6
33 factor viii deficiency 10.6 F2 F5
34 mesenteric vascular occlusion 10.6 F2 MTHFR
35 catastrophic antiphospholipid syndrome 10.6 F5 MTHFR
36 ischemic neuropathy 10.6 F2 MTHFR
37 headache 10.6
38 transient cerebral ischemia 10.5
39 scott syndrome 10.5 F2 F5
40 migraine with aura 10.5
41 buerger disease 10.5 F2 MTHFR
42 acute liver failure 10.5 F2 F5
43 intestinal impaction 10.4 F2 SERPINC1
44 fournier gangrene 10.4 F2 SERPINC1
45 severe hemophilia a 10.4 F2 F5
46 leech infestation 10.4 F2 SERPINC1
47 sleep apnea 10.4
48 alpha-2-plasmin inhibitor deficiency 10.4 F2 SERPINC1
49 giant hemangioma 10.4 F2 SERPINC1
50 apnea, obstructive sleep 10.4

Graphical network of the top 20 diseases related to Patent Foramen Ovale:



Diseases related to Patent Foramen Ovale

Symptoms & Phenotypes for Patent Foramen Ovale

MGI Mouse Phenotypes related to Patent Foramen Ovale:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 SERPINC1 TBX20 F2 TBX5 F5 GATA4
2 homeostasis/metabolism MP:0005376 9.85 F12 TBX20 F2 TBX5 F5 GATA4
3 embryo MP:0005380 9.8 SERPINC1 TBX20 F2 TBX5 F5 GATA4
4 mortality/aging MP:0010768 9.61 SERPINC1 TBX20 F2 TBX5 F5 GATA4
5 normal MP:0002873 9.1 F12 TBX20 F2 TBX5 GATA4 NKX2-5

Drugs & Therapeutics for Patent Foramen Ovale

Drugs for Patent Foramen Ovale (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
2
Warfarin Approved Phase 4,Phase 2,Phase 3 81-81-2 6691 54678486
3
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-78-2 2244
4 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
5 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Not Applicable
6 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
7 Antipyretics Phase 4,Phase 2,Phase 3,Not Applicable
8 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
10 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
11 Anticoagulants Phase 4,Phase 3,Phase 2
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Not Applicable
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Coagulants Phase 4
16
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
17
Dipyridamole Approved Phase 3,Phase 2,Not Applicable 58-32-2 3108
18
Apixaban Approved Phase 3,Phase 2 503612-47-3 10182969
19
Rivaroxaban Approved Phase 3 366789-02-8
20
Serine Approved, Nutraceutical Phase 3,Phase 2 56-45-1 5951
21 Dabigatran Phase 3
22
protease inhibitors Phase 3,Phase 2
23 Serine Proteinase Inhibitors Phase 3,Phase 2
24 HIV Protease Inhibitors Phase 3,Phase 2
25 Pharmaceutical Solutions Phase 3,Phase 2
26 Factor Xa Inhibitors Phase 3,Phase 2
27 Aspirin, Dipyridamole Drug Combination Phase 3,Not Applicable
28 Antithrombin III Phase 3,Phase 2
29 Antithrombins Phase 3,Phase 2
30 Antivitamins K Phase 3
31
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
32
Polidocanol Approved Phase 2 9002-92-0
33
Dalteparin Approved Phase 2 9005-49-6
34 calcium heparin Phase 2
35 Neurotransmitter Agents Phase 2,Not Applicable
36 Heparin, Low-Molecular-Weight Phase 2
37 Anticonvulsants Phase 2
38 Antidepressive Agents Phase 2
39 Purinergic P2 Receptor Antagonists Phase 2
40 Purinergic P2Y Receptor Antagonists Phase 2
41 Calcium, Dietary Phase 2
42
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
43
Iodine Approved, Investigational Not Applicable 7553-56-2 807
44
Nitric Oxide Approved Not Applicable 10102-43-9 145068 160954
45
Vitamin C Approved, Nutraceutical Not Applicable 50-81-7 5785 54670067
46
Tocopherol Approved, Investigational, Nutraceutical Not Applicable 1406-66-2 14986
47
Vitamin E Approved, Nutraceutical, Vet_approved Not Applicable 59-02-9 14985
48 tannic acid Approved, Nutraceutical
49
N,N-dimethylarginine Experimental Not Applicable 30315-93-6 123831
50 Micronutrients Not Applicable

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism Unknown status NCT00166257 Phase 4 Medical antitrhombotic treatment
2 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function Unknown status NCT02509754 Phase 4
3 Patent Foramen Ovale in Cryptogenic Stroke Study Completed NCT00697151 Phase 4 Warfarin;Aspirin
4 Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO) Recruiting NCT01550588 Phase 4 Standard medical treatment
5 Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO) Unknown status NCT00201461 Phase 2, Phase 3 Best medical therapy
6 MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant Unknown status NCT00283738 Phase 2, Phase 3
7 Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence Completed NCT00562289 Phase 3 aspirin;Antivitamins K or rivaroxaban or dabigatran or apixaban
8 Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent Completed NCT00506493 Phase 3
9 Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study Completed NCT00431834 Phase 3
10 Cardiox Shunt Detection Technology Study Terminated NCT01333761 Phase 3
11 Right to Left Cardiac Shunt Detection Terminated NCT01773252 Phase 3
12 ESCAPE Migraine Trial Terminated NCT00267371 Phase 3 Medical management/current medications per standard of care by personal physician.
13 RESPECT PFO Clinical Trial Unknown status NCT00465270 Phase 2
14 Premium Migraine Trial Completed NCT00355056 Phase 2
15 Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt Completed NCT00442364 Phase 2 Polidocanol (1%) Microfoam (Varisolve)
16 Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches Recruiting NCT02777359 Phase 2
17 Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile Not yet recruiting NCT03500939 Phase 2 Medical oxygen
18 PRIMA PFO Migraine Trial Terminated NCT00505570 Phase 2
19 Catheter Thrombectomy in Patients With Massive Pulmonary Embolism Terminated NCT00314002 Phase 1, Phase 2
20 Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli Withdrawn NCT02378623 Phase 2 Apixaban;Placebo
21 PFO Closure for Obstructive Sleep Apnoea Unknown status NCT02771561 Not Applicable
22 Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler Unknown status NCT02383836
23 Timing of Closure of Patent Foramen Ovale Following Birth Unknown status NCT01032785
24 Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale Unknown status NCT01149447
25 Occluder Size Determination in Transcatheter ASD II Closure Based on 3D TEE Assessment Unknown status NCT02601768
26 Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism Unknown status NCT00196027 Not Applicable
27 InterSEPT: In‐Tunnel SeptRx European PFO Trial Unknown status NCT01385670 Not Applicable
28 Chronic Mountain Sickness, Systemic Vascular Function Unknown status NCT01182792 Not Applicable
29 Clinical Proteomic Research for the Brain Unknown status NCT00983723
30 Quantitative End Tidal CO2 Monitoring in the Delivery Room (DR) Unknown status NCT01381068 Not Applicable
31 Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP) Completed NCT01257880
32 Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale Completed NCT01216423
33 Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke Completed NCT03416426
34 Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine Completed NCT02127294 Not Applicable
35 Safety and Effectiveness Study of the Solysafe Septal Occluder in Patients With Atrial Septum Defect and Patent Foramen Ovale Completed NCT00207376 Not Applicable
36 Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO) Completed NCT00831259
37 Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries Completed NCT02400892
38 Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure Completed NCT01854281
39 Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea Completed NCT01780207 Not Applicable
40 Patent Foramen Ovale in Children With Migraine Headaches Completed NCT00750594
41 Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System Completed NCT00968032 Not Applicable
42 GORE® Septal Occluder European Union Clinical Evaluation Completed NCT01605851 Not Applicable
43 Correlation of Right-left Shunt Detection in Cardioembolism Etiology in Stroke Patient. Completed NCT02351076
44 Cardiac Troponin T After Transcatheter Closure of the Interatrial Septum Completed NCT03099967
45 Long-term Safety Study of the GORE® HELEX® Septal Occluder Completed NCT00581308 Not Applicable
46 Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis Completed NCT03377465 Not Applicable
47 The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness Completed NCT00196040 Not Applicable
48 Semi-automatic assessMent of Aortic Roots by Three-dimensional transoEsophageal echocaRdiography (SMARTER) Completed NCT02724709
49 Surgical Tourniquets and Cerebral Emboli Completed NCT02240732
50 Identification the Cause of Silent Cerebral infarctiON in Healthy Subjects (ICONS) Completed NCT01429948

Search NIH Clinical Center for Patent Foramen Ovale

Cochrane evidence based reviews: foramen ovale, patent

Genetic Tests for Patent Foramen Ovale

Genetic tests related to Patent Foramen Ovale:

# Genetic test Affiliating Genes
1 Patent Foramen Ovale 29

Anatomical Context for Patent Foramen Ovale

MalaCards organs/tissues related to Patent Foramen Ovale:

41
Heart, Lung, Brain, Spinal Cord, Liver, Testes, Endothelial

Publications for Patent Foramen Ovale

Articles related to Patent Foramen Ovale:

(show top 50) (show all 782)
# Title Authors Year
1
Cerebral infarction following cyanoacrylate endoscopic therapy of duodenal varices in a patient with a patent foramen ovale. ( 29948836 )
2018
2
Intracardiac echocardiography for percutaneous patent foramen ovale and atrial septal defect occlusion. ( 29374291 )
2018
3
Adding patent foramen ovale closure to antiplatelet drugs reduced ischemic stroke after cryptogenic stroke. ( 29335718 )
2018
4
Paradoxical emboli following a pulmonary embolus in the presence of a patent foramen ovale. ( 29404367 )
2018
5
Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials. ( 29356972 )
2018
6
Closure of patent foramen ovale for cryptogenic stroke patients: an updated systematic review and meta-analysis of randomized trials. ( 29383514 )
2018
7
Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample. ( 29422265 )
2018
8
Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine. ( 29914296 )
2018
9
Multiple Cerebral Infarctions Due to Patent Foramen Ovale in a Patient with Eosinophilic Granulomatosis with Polyangiitis. ( 29373226 )
2018
10
A Novel ATP1A2 Gene Variant Associated With Pure Sporadic Hemiplegic Migraine Improved After Patent Foramen Ovale Closure: A Case Report. ( 29867740 )
2018
11
Odyssey of Patent Foramen Ovale: Closure in Cryptogenic Stroke: The Canary in the Coal Mine of Clinical Trials? ( 29910194 )
2018
12
Patent foramen ovale closure vs. medical therapy for recurrent stroke prevention: Evolution of treatment effect during follow-up. ( 29338916 )
2018
13
Biventricular Noncompaction Cardiomyopathy Accompanied by Severe Pulmonary Valvular Stenosis and Patent Foramen Ovale. ( 29911014 )
2018
14
The use of point-of-care ultrasound to diagnose patent foramen ovale in elective hip and knee arthroplasty patients and its association with postoperative delirium. ( 29368313 )
2018
15
A rare case of paradoxical embolism from tricuspid valve infective endocarditis and patent foramen ovale. ( 29372516 )
2018
16
Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study. ( 29910193 )
2018
17
Patent Foramen Ovale Closure for Stroke Prevention and Other Disorders. ( 29910192 )
2018
18
Is Patent Foramen Ovale a Risk Factor for Perioperative Stroke? ( 29411017 )
2018
19
A young woman with a symptomatic patent foramen ovale: Natasha's fascinating story. ( 29904322 )
2018
20
Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials. ( 29887476 )
2018
21
Adding patent foramen ovale closure to antiplatelet therapy reduced stroke after cryptogenic stroke. ( 29335719 )
2018
22
Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis. ( 29335335 )
2018
23
Patent foramen ovale in older patients with cryptogenic stroke or transient ischaemic attack. ( 29887163 )
2018
24
Tissue Plasminogen Activator to Treat a Stroke after Foam Sclerotherapy in a Woman with a Patent Foramen Ovale. ( 29402614 )
2018
25
Patent foramen ovale after cryptogenic stroke: When is it justifiable to close it? ( 29887477 )
2018
26
Novel Association of Juvenile Polyposis Syndrome With Atrial Septal Aneurysm and Patent Foramen Ovale: A Case Report. ( 29634562 )
2018
27
Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials. ( 29955915 )
2018
28
Patent foramen ovale and migraine with aura in a retrospective analysis: age matters. ( 29904837 )
2018
29
Patent Foramen Ovale and Risk of Perioperative Stroke-Reply. ( 29946721 )
2018
30
Patent Foramen Ovale Repair at the Time of Double Lung Transplantation: Necessary or Not? ( 29349838 )
2018
31
Patent Foramen Ovale and Risk of Perioperative Stroke. ( 29946718 )
2018
32
Very late migration to and retrieval of an Amplatzer patent foramen ovale occlusion device from the abdominal aortic carrefour. ( 29894354 )
2018
33
Association of Preoperatively Diagnosed Patent Foramen Ovale With Perioperative Ischemic Stroke. ( 29411032 )
2018
34
Closure of the patent foramen ovale, if only a stitch in time saved nine. ( 29893689 )
2018
35
Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis. ( 29887162 )
2018
36
Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrombotic therapy: A meta-analysis of 6 randomised clinical trials and 3560 patients with reconstructed time-to-event data. ( 29901447 )
2018
37
Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al. ( 29955916 )
2018
38
Cochleovestibular Transient Ischemic Attack as a Manifestation of Patent Foramen Ovale. ( 29360095 )
2017
39
Role of closure of patent foramen ovale in cryptogenic stroke: Current status. ( 29916427 )
2017
40
Patent foramen ovale and anticardiolipin antibodies, a strange cause of bilateral kidney infarcion. ( 28826574 )
2017
41
Patent Foramen Ovale and Migraine Headache. ( 28886844 )
2017
42
Effect of a patent foramen ovale in humans on thermal responses to passive cooling and heating. ( 28819008 )
2017
43
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. ( 28902590 )
2017
44
An unusual combination of patent foramen ovale with pulmonary arteriovenous malformation in a young patient with stroke. ( 28681775 )
2017
45
Concomitant coronary and pulmonary embolism associated with patent foramen ovale: A case report. ( 29384941 )
2017
46
Ischemic Stroke in a Patient With Quadricuspid Aortic Valve and Patent Foramen Ovale. ( 28868103 )
2017
47
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. ( 28902580 )
2017
48
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. ( 28902593 )
2017
49
Patent Foramen Ovale after Cryptogenic Stroke - Assessing the Evidence for Closure. ( 28902595 )
2017
50
Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment. ( 28886840 )
2017

Variations for Patent Foramen Ovale

ClinVar genetic disease variations for Patent Foramen Ovale:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 AAR2 NM_015511.4(AAR2): c.520G> A (p.Val174Met) single nucleotide variant Likely pathogenic rs746800707 GRCh38 Chromosome 20, 36240388: 36240388
2 AAR2 NM_015511.4(AAR2): c.520G> A (p.Val174Met) single nucleotide variant Likely pathogenic rs746800707 GRCh37 Chromosome 20, 34828310: 34828310
3 46;XX;inv(7)(q21.2q34) inversion Likely pathogenic
4 TRPM4 NM_017636.3(TRPM4): c.1376G> A (p.Arg459His) single nucleotide variant Conflicting interpretations of pathogenicity rs142312281 GRCh38 Chromosome 19, 49182690: 49182690
5 TRPM4 NM_017636.3(TRPM4): c.1376G> A (p.Arg459His) single nucleotide variant Conflicting interpretations of pathogenicity rs142312281 GRCh37 Chromosome 19, 49685947: 49685947
6 RNF213 NM_001256071.2(RNF213): c.11659A> G (p.Lys3887Glu) single nucleotide variant Uncertain significance GRCh38 Chromosome 17, 80363699: 80363699
7 RNF213 NM_001256071.2(RNF213): c.11659A> G (p.Lys3887Glu) single nucleotide variant Uncertain significance GRCh37 Chromosome 17, 78337499: 78337499

Expression for Patent Foramen Ovale

Search GEO for disease gene expression data for Patent Foramen Ovale.

Pathways for Patent Foramen Ovale

Pathways related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 F12 F2 F5 GATA4 SERPINC1
2
Show member pathways
12.52 GATA4 MYH6 NKX2-5 TBX5
3
Show member pathways
12.48 F12 F2 F5 SERPINC1
4
Show member pathways
11.91 GATA4 NKX2-5 TBX5
5
Show member pathways
11.76 F12 F2 F5 SERPINC1
6 11.7 GATA4 NKX2-5 TBX5
7 11.61 GATA4 MED13L MYH6
8 11.6 F12 F2 F5 SERPINC1
9 10.92 GATA4 NKX2-5 TBX20 TBX5
10 10.78 GATA4 NKX2-5
11 10.75 GATA4 MYH6 NKX2-5 TBX20 TBX5
12 10.1 GATA4 NKX2-5

GO Terms for Patent Foramen Ovale

Cellular components related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-DNA complex GO:0032993 8.62 NKX2-5 TBX5

Biological processes related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 GATA4 NKX2-5 TBX20 TBX5
2 heart development GO:0007507 9.8 GATA4 NKX2-5 TBX5
3 cellular protein metabolic process GO:0044267 9.77 F2 F5 SERPINC1
4 blood coagulation GO:0007596 9.65 F12 F2 F5 GATA4 SERPINC1
5 heart looping GO:0001947 9.63 GATA4 NKX2-5 TBX20
6 sarcomere organization GO:0045214 9.62 MYH6 NKX2-5
7 positive regulation of cardiac muscle cell proliferation GO:0060045 9.61 TBX20 TBX5
8 blood circulation GO:0008015 9.61 F5 MTHFR TBX20
9 ventricular septum development GO:0003281 9.59 GATA4 TBX5
10 outflow tract septum morphogenesis GO:0003148 9.58 NKX2-5 TBX20
11 embryonic heart tube development GO:0035050 9.58 NKX2-5 TBX20
12 fibrinolysis GO:0042730 9.57 F12 F2
13 blood coagulation, intrinsic pathway GO:0007597 9.56 F12 F2
14 cardiac muscle tissue morphogenesis GO:0055008 9.55 NKX2-5 TBX20
15 adult heart development GO:0007512 9.54 MYH6 NKX2-5
16 cardiac muscle cell differentiation GO:0055007 9.54 GATA4 NKX2-5 TBX5
17 cardiac right ventricle morphogenesis GO:0003215 9.52 GATA4 TBX20
18 positive regulation of blood coagulation GO:0030194 9.51 F12 F2
19 regulation of blood coagulation GO:0030193 9.5 F12 F2 SERPINC1
20 endocardial cushion development GO:0003197 9.49 GATA4 TBX5
21 cardiac ventricle morphogenesis GO:0003208 9.48 GATA4 NKX2-5
22 hemostasis GO:0007599 9.46 F12 F2 F5 SERPINC1
23 bundle of His development GO:0003166 9.4 NKX2-5 TBX5
24 positive regulation of cardioblast differentiation GO:0051891 9.13 GATA4 NKX2-5 TBX5
25 atrial septum morphogenesis GO:0060413 8.92 GATA4 NKX2-5 TBX20 TBX5

Molecular functions related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding GO:0001228 8.8 GATA4 NKX2-5 TBX5

Sources for Patent Foramen Ovale

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....